… The focus of this article is on approved PCSK9 … Evolocumab is also indicated for use in
adults and adolescents aged ≥12 years with homozygous familial hypercholesterolemia in …

… As results of that, more attention should be paid to the treatment of hyperlipidemia. Due to
… Cicero, Retargeting the management of hypercholesterolemia focus on evolocumab, Ther. …

Passive antibody therapies have a long history of use. In the 19th century, antibodies from
xenographic sources of polyclonal antibodies were used to treat infections (diphtheria). They …

… The final aim focused on the synthesis of a nanoparticle-based drug delivery platform that
employs antibodies as targeting agents for increased treatment specificity. We demonstrated …

The advancements in technology and manufacturing processes have allowed the development
of new derivatives, biosimilar or advanced improved versions for approved antibodies …

Biologics currently account for more than 25% of FDA approved entities, and this percentage
is expected to increase. Biologics have been very successful in the treatment of major …

… management of cardiovascular diseases. Clinicians and experimental researchers have started
focusing on … non-human primates [138] has been retargeted to deliver siRNA [139], small …

… Patients with RMS constitute a common target for current treatment options [5]. … counts),
and a decrease with time in the active treatment groups. Different models were tested, including …